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The impression among Arab Physicians dealing with breast cancer is that it presents at an earlier age and
at a more advanced stage as compared to western countries. However, the statistical data to support this
impression is remarkably scarce.
Method: We performed a comprehensive literature review of reports of breast cancer in Arab countries.
Articles were identiﬁed from Saudi Arabia, Bahrain, Qatar, Kuwait, Emirate, Oman, Yemen, Iraq, Syria,
Jordan, Lebanon, Egypt, Libya, Algeria, Tunis, Morocco, and Sudan.
Results: Twenty eight articles were identiﬁed and reviewed. The average age at diagnosis of breast cancer
was available in 18 articles; the average age was 48 (SD ¼ 2.8), range 43e52, median 48.5 and mode 45
years among the 7455 patients included. The median age of diagnosis of breast cancer was available in 8
articles; here, the average age was 45.4 (SD ¼ 4.8), range 40e54.5, median 44.5 years among the 5379
patients included. The percentage of patients that were younger than 50 years old was reported in 11
articles from 8 countries and included 5144 patients; 65.5% (SD ¼ 11) were less than 50 years old (range
49e78%, median ¼ 66%).
Discussion: In this literature review, the average age at presentation of breast cancer in Arab countries
appears to be a decade earlier than in western countries. If this is true, this has important implications for
screening and cancer management strategies in these countries, including the ideal age at which to begin
screening. Adoption of Western guidelines “without critical amendment” in planning breast cancer
programs will waste resources without achieving desired outcomes. Determination of the true frequency
and age of onset of breast cancer in Arab women should be an important research priority.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The Arab world has a population of approximately 301,227,000
(2004), living in 22 countries spread across Northern Africa and
Western Asia, including the Middle East.1 Originating in the Arab
peninsula, population migration has continued throughout history.
Arabs share common demographic features that include high rates
of consanguinity, large family size and rapid population growth.
There is a high frequency of autosomal recessive disorders and an
increased frequency of homozygocity for autosomal dominant
traits which have made certain disorders more prevalent in Arabs,
for example, renal osteoporosis and renal tubular acidosis, Meckel’s
syndrome, and autosomal recessive severe childhood muscular
dystrophy.2 Breast cancer is the most common cancer among
women in Arab countries.1 Even so, the exact volume and burden of
the disease is not known.argaret Hospital, University
ty Avenue, Toronto, Ontario,
946 4429.
ciates Ltd. Published by Elsevier LtThe impression among Arab physicians dealing with breast
cancer is that it presents at an earlier age and at a more advanced
stage than in western countries. However, the statistical data to
support this impression is remarkably scarce. Most cancer regis-
tries in Arab countries are not publically available, data may not be
gathered consistently, and data is not available or used to answer
research questions.
Breast cancer that presents at a younger age generally has more
aggressive cellular features resulting in more aggressive clinical
behaviour, more advanced stage at presentation, and poorer
prognosis.3 Treatment strategies are therefore also more aggres-
sive, and often include chemotherapy and radiation in addition to
surgery. Age at diagnosis therefore has important implications
when planning breast cancer treatment units in terms of personnel,
drugs, equipment and ﬁnancial resources.
In addition, before the availability of breast imaging, the control
of breast cancer relied entirely on the successful treatment of
palpable disease. Today breast cancer control is signiﬁcantly
improved by the ability to diagnose the disease at a more favour-
able stage, such as when cells have not crossed the basement
membrane (in situ), or when the invasive disease is too small to bed. All rights reserved.
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mammography have reduced breast cancer mortality in western
countries;4 the implementation of screening programs in Arab
nations is inevitable. Age at diagnosis will critically impact the
choice of screening strategy. If breast screening programs are to be
implemented in Arab countries, at what age shouldmammographic
screening be started, and is mammography the best imaging
modality?
By reviewing the available literature produced by researchers in
Arab countries, we aim to use evidence-based information to test
the hypothesis that the presentation of breast cancer occurs at
a younger age group in Arab women.
2. Materials and methods
All available abstracts and articles about breast cancer that
discussed age at diagnosis of breast cancer in Arabs, either as its
primary subject or considered within the context of that article,
have been reviewed. An information specialist through Medline
and Embase performed a systematic search. In addition, a personal
search was done for each Arab country. Search terms used included
“Age at diagnosis of breast neoplasm, Breast tumour, breast cancer,
intraductal, noniﬁltrating, lobular”; these were combined with
“Arabs, middle east and each country included”. Speciﬁc countries
included are Saudi Arabia, Bahrain, Qatar, Kuwait, Emirate, Oman,
Yemen, Iraq, Syria, Jordan, Lebanon, Egypt, Libya, Algeria, Tunis,
Morocco, and Sudan. The data searched for were average, median
and percentage of the population under study that is younger than
50 years old at the time of diagnosing breast cancer. Patients in the
articles that were discussed under speciﬁc groups like male breast
cancer, breast cancer in pregnancy, familial breast cancer, pre or
postmenopausal breast cancer, breast cancer related to BRCA genes
were not included in this search. Data were collected on Access
form e Microsoft 2007 and analysed. Some Countries were also
excluded because published articles mentioning age at diagnosis of
breast cancer could not be traced (Syria, Morocco and Iraq).Table 1
Age at diagnosis of breast cancer in Arab countries.
Country Author Year published Study desi
Algeria Nancy5 2008 Case series
Bahrain Al Saad6 2006 Case series
Egypt Bedwani7 2001 Case series
Hussein8 2004 Cross secti
Emirate Denic9 2005 Case contr
Thanaa10 1997 Case series
Jordan Abu Salem11 2002 Case series
Amr12 1985 Case series
Dajani13 1987 Case series
Kuwait Paszko14 1993 Case series
Lebanon El saghir15 2002 Case series
Libya Akhtar16 1993 Case series
Oman Al-Moundhri17 2004 Case series
Qatar Rasul18 2003 Case series
Saudi Arabia Al Idrissi19 1992 Case series
Elkum20 2007 Case contr
Ezzat21 1999 Case series
Ibrahim22,23 1998 Case series
2005 Case series
Mansoor24 2001 Case series
Sudan KD AwadelKarim25 2007 2 Case Seri
Tunis Ayadi L26 2008 Case series
Ben Ahmed27 2002 Case series
Labidi28 2000 Case series
Maalej M29,30 1999 Case series
2008 Case series
Sahraoui31 2006 Case series
Yemen Althobhani32 2006 Case series3. Results
On Medline search (1950e2008, 1st week of November), 77
abstracts were produced using the search strategy. Only 4 met the
criteria for inclusion. On Embase search (1980e2008 week 47) 35
abstracts were produced with 7 meeting the inclusion criteria. Two
were excluded, however, because data regarding age was not
mentioned in 1, while the other article could not be traced. The
other 19 articles were produced after speciﬁc search per country in
Medline and Yahoo. An additional 2 articles were excluded because
the study used the age of 45 years as the cut-off rather than 50
years of age. After all exclusions, there were 28 article included.
Table 1 summarizes the results.3.1. Average age at diagnosis of breast cancer
The average age at diagnosis of breast cancer was available in 18
articles from 11 countries (Egypt (1), Emirate (2), Jordan (3), Kuwait
(1), Lebanon (1), Oman (1), Qatar (1), Saudi Arabia (1), Sudan (1),
Tunis (5) and Yemen (1)) (Table 1). From these articles, the average
age was 48 (SD ¼ 2.8), weighted average was 49.8, range 43e52,
median 48.5 and mode 45 years. The total number of patients
included in these studies was 7455 (Table 2).3.2. Median age at diagnosis of breast cancer
The median age of diagnosis of breast cancer was available in 8
articles produced in 4 countries (Bahrain (1), Egypt (1), Saudi Arabia
(5) and Tunis (1)). From these articles, the average age was 45.4 (SD
4.8), weighted average 49.4, range 40e54.5, median 44.5 years. The
total number of patients included was 5379 (Table 2).
For all averages and medians (pooled average and median), the
weighted average was 49.6 for total number of patients of 12,839
(Table 3).gn Period patients Average Median <50 (%)
NA 66
1999e2005 35 50 67
1990e2000 2860 54.5
onal NA 53 43
ol NA 72 49
NA 228 48
1998e2001 44 46
NA 45
1980e1985 228 45
NA 315 52 78
1983e2000 2673 50 49
1981e1985 335 72.3
1996e2002 152 48
1991e2001 70 48
1981e1990 130 40 66
ol 1986e2002 867 45
1981e1991 315 46 64
1985e1995 292 42 78
1992e2001 780 42 78
NA 300 49
es 2004e2005 114 52 51
2000e2004 155 52 51.6
1990e1998 729 50
1994e2000 100 44
1994 689 50
2004 1437 51
1993e2002 41 45
NA 155 45
Table 2
Summery of all results.
Breast cancer Countries included Average (SD) Range Median Mode Total patients
number
Total number
of studies
For all averages of age at diagnosis Egypt, Emirate, Jordan, Kuwait, Lebanon,
Oman, Qatar, Saudi Arabia, Sudan, Tunis, Yemen
48 (2.8) 43e52 48.5 45 7455 18
For all medians of Age at diagnosis Bahrain, Egypt, Saudi Arabia, Tunis 45.4 (4.8) 40e54.5 44.5 42 5379 8
For all proportions in the study population
that is younger than 50 years old
Algeria, Bahrain, Kuwait, Lebanon, Libya,
Saudi Arabia, Sudan, Tunis
65.5% (11) 49e78% 66% 78% 5144 11
Table 4
Total population and median age of the population (WHO 2006) and age stan-
dardized incidence rate of breast cancer comparing Arab countries with selected
Western nations (International Agency for Research on Cancer 2002). The incidence
of breast cancer is signiﬁcantly lower in Arab nations, and their average population is
younger than in Western nations.
Country Total population
103 (2006)33
Median
age (2006)33
Age standardized incidence
rate of breast cancer per
100,000a (2002)34
Algeria 33,351 24 32.5
Egypt 74,166 23 24.2
Jordan 5729 21 33
Kuwait 2779 29 31.8
Lebanon 4055 27 52.5
Libya 3408 25 23.4
Morocco 30,853 25 22.5
Oman 2546 23 13.2
Qatar 821 31 33.3
Saudi Arabia 24,175 24 24.7
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years old
The percentage of patients younger than 50 years old in each
study population was not the primary intention of this search. It
was, however, stated in 11 articles produced from 8 countries
(Algeria (1), Bahrain (1), Kuwait (1), Lebanon (1), Libya (1), Saudi
Arabia (4), Sudan (1) and Tunis (1)). Across these articles, 65.5%
(SD ¼ 11) on average were less than 50 years of age (range 49e78%,
median of 66%). The total number of patients was 5144 (Table 2).
4. Discussion
In this literature review, the average age at presentation of
breast cancer in Arab women is shown to be a decade earlier than
western countries. Across 18 articles, the average and median
averages were 48 and 48.5 years old, respectively. Moreover, 65.6%
of the patients were younger than 50 years old in 11 studies (Table
2). The explanation could be related to the fact that Arab nations
have younger population compared to western countries; the
median age is almost one decade younger according to WHO
statistics33 (Table 4). However, these ﬁndings do support the
hypothesis that breast cancer may present at an earlier age in Arab
women.
The age standardized incidence rate for breast cancer in Arab
women is approximately one fourth to one third that of Western
women34 (Table 4). This signiﬁcant difference may be related to
different risk factors. However, there are 2 interesting studies
which possibly raise an alarm regarding the prevalence of breast
cancer. The ﬁrst is from Egypt, where 4116 women aged 35e64
were screened in a deﬁned geographical area. Eight breast cancer
cases per 1000 women were detected initially and 2 more cases
were added on rescreening.35 The second study is from Tunisia,
where free screening mammography was offered to 2200 women
aged 40e70. Twenty-four percent had a positive test, and 4.5
cancers were detected per 1000 women.36 These studies suggest
that breast cancer may be more common than expected. More
research is needed to demonstrate the actual prevalence of breast
cancer in Arab nations.
This data suggests that there may be clear social, economic and
population differences in the age of presentation of breast cancer
between Arab and Western populations. We did not compare the
stage of presentation of breast cancer in Arab women as comparedTable 3
Weightedstatistics for age at presentation.
Statistic Number of
studies
Total sample
size
Weighted
averagea
Average 17 7455 49.8
Median 8 5379 49.4
Pooled Average/Median 25 12839 49.6
a An average where each individual is assigned a weight proportional to its
sample size. A weight for a study is calculated as the study sample size divided by
the total sample size (over all the studies with a non-missing average).to Western populations as this information difﬁcult to obtain, but
such research is a necessary next step. The effect of such differences
could result in signiﬁcant alterations in disease presentation and
behaviour. As a result, adoption of Western guidelines “without
critical amendment” in planning for managing breast cancer would
not yield the same results, and resources utilised might be wasted
without achieving desired outcomes.
Screening would have no beneﬁt if not followed by treatment
(including surgery), and treatment is likely to be more effective if
cancer is detected at earlier stage by screening. The combination of
screening and treatment has an overall estimated reduction in
death from breast cancer of 24.9e38.3%. The contribution of breast
screening to this reduction is 28e65% (median, 46%).37 The
importance of mammographic breast screening is obvious;
currently it is probably the single most important strategy to
decrease mortality from breast cancer. Meta-analyses of random-
ized controlled trials demonstrate a 7e23% reduction in breast
cancer mortality rates with screening mammography in women
40e49 years of age.38 At present nationwide breast screening
programs in Arab countries do not exist. However, with the
increased awareness regarding breast cancer and the prosperity
that many Arab countries are experiencing, the implementation of
such programs is inevitable.
The recommendation inWestern practice is to start screening at
the age of 50 years [National Health Service (NHS),39 EuropeanTunisia 10,215 27 19.6
Emirates 4248 30 24.1
Yemen 21,732 17 35.1
Canada 32,577? 39 84.3
France 861,330 39 91.9
Germany 86,641 42 79.8
Italy 58,779 42 74.4
UK 60,512 39 87.2
USA 302,841 36 101.2
a Age-standardized incidence rate is the number of new cases of cancer or cancer
deaths per 100,000 that would have occurred in the standard population if the
actual age-speciﬁc rates observed in a given population had prevailed in the stan-
dard population.
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(IARC)41,42]. As a concept, breast screening should start 5e10 years
earlier than the age group in which breast cancer is commonly
diagnosed.43 If the average population in Arab nations is one
decade younger than Western nations, and the presentation of
breast cancer is truly in the 40e50 year age group, it would seem
unreasonable to commence screening at age 50 years of age. A
signiﬁcant proportion of women having sub clinical breast cancer
would not be included. Starting breast screening in Arab women at
age of 40 years old needs to be explored. This will be similar to
many major US medical organizations that in reality recommend
screening mammography for women aged 40 years and older.44e46
The optimal screening modality would also need to be explored.
Certainly, screening mammography is less sensitive in younger
women, mainly due to increased breast density that can obscure
the radiological features of early breast cancer. However, magnetic
resonance imaging (MRI) has proved to clarify ambiguous lesion on
mammograms. In fact, strategies that combined MRI plus
mammography with or without ultrasound and clinical breast
examination reported sensitivities of 93e100%47 and could poten-
tially be investigated in a randomised fashion as a screening
modality in young Arab women.
Unfortunately, breast cancer that present in young women
generally have poorer clinicopathologic variables [larger size,
lymph node positive, poorly differentiated, higher ER and PR
receptors negativity and higher human epidermal growth factor
receptor 2 (HER-2)] which suggest aggressive behaviour.48e50 This
clearly has implications on treatment options. For example, breast
conserving surgery is generally appreciated by young patients,
along with a satisfactory negative surgical margin and the subse-
quent application of high quality radiotherapy. Aggressive chemo-
therapy with all its side effects and complications is often
necessary. Hormonal therapy should not be used in oestrogen and
progesterone receptors negative patients. Treatments need to
follow standard protocols to avoid inappropriate management and
non-compliance. Reconstructive breast service should be offered. A
comprehensive plan that includes training in the different disci-
plines required, establishment of specialised breast units, provision
of equipments, and adequate ﬁnancial support is required to care
for these patients properly.
In addition, youngwomenmight have critical personal concerns
such as work, family commitments that include raising children,
and other life matters that should be considered in programs
created for breast care. Breast care programmes can include but not
limited to children care services, home care, transport services,
ﬁnancial support, protecting work policies and community support
centers that include volunteers and support groups.
Finally, planning without data that continuously produces
useful and reliable information speciﬁc to each population can
lead to structures and processes that produce unsatisfying
outcomes. Researchers in the ﬁeld have noticed the scarcity of
data and researches related to breast cancer in Arabic countries.
The creation of a breast cancer data bank would be an important
ﬁrst step in the improvement of breast cancer care in Arabic
countries. Other strategies could include more investment in
structuring national registries, systematic registration of patients
and funding and training local researchers. If data are properly
and reliably collected, summarized and analyzed by professional
researchers, the information obtained will aid tremendously and
accurately in planning according to the needs of the population
living in Arab countries.
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